Table 2.
CR | NR | NE | |
---|---|---|---|
All Patients (n=45) | 30 (67%) | 11 (24%) | 4 (9%) |
Response by Age | |||
≤ 50 (n=5) | 3 (60%) | 0 (0%) | 2 (40%) |
51–59 (n=16) | 14 (88%) | 1 (6%) | 1 (6%) |
≥ 60 (n=24) | 13 (54%) | 10 (42%) | 1 (4%) |
Response by Poor Risk Biologic Features | |||
Etiology | |||
MDS/AML (n=23) | 15 (65%) | 7 (30%) | 1 (4%) |
MPD/AML (n=5) | 2 (40%) | 3 (60%) | 0 (0%) |
T-AML (n=9) | 8 (89%) | 0 (0%) | 1 (11%) |
Genetics | |||
Adverse Cyto (n=24) | 16 (67%) | 7 (30%) | 1 (3%) |
FLT-3 (n=9) | 8 (89%) | 0 (0%) | 1 (11%) |
Proliferation | |||
Blasts ≥ 20,000/mm3 (n=15) | 9 (60%) | 5 (33%) | 1 (7%) |
Pretreatment HU (n=6) | 3 (50%) | 2 (33%) | 1 (17%) |